The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
about
The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad.Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogeneReport of chronic myeloid leukemia from SEAROC experience, Jaipur over a period of 9 years.Report of chronic myeloid leukemia in chronic phase from Cancer Institute (Women India Association), Chennai, 2002-2009.In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow.Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour.
P2860
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
@ast
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
@en
The use of imatinib
@nl
type
label
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
@ast
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
@en
The use of imatinib
@nl
prefLabel
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
@ast
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
@en
The use of imatinib
@nl
P2093
P1433
P1476
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations
@en
P2093
David Marin
Eduardo Olavarria
Jane F Apperley
John M Goldman
Lorraine Armstrong
Sarah Marktel
P304
P577
2002-09-01T00:00:00Z